Johnson & Johnson (NYSE:JNJ) Shares Acquired by Pathway Financial Advisors LLC

Pathway Financial Advisors LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,438 shares of the company’s stock after buying an additional 226 shares during the period. Pathway Financial Advisors LLC’s holdings in Johnson & Johnson were worth $852,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Mascoma Wealth Management LLC boosted its holdings in Johnson & Johnson by 12.0% in the third quarter. Mascoma Wealth Management LLC now owns 1,966 shares of the company’s stock valued at $306,000 after purchasing an additional 210 shares during the last quarter. Key Bridge Compliance LLC purchased a new stake in Johnson & Johnson in the third quarter valued at $1,090,000. Auour Investments LLC boosted its holdings in Johnson & Johnson by 32.2% in the third quarter. Auour Investments LLC now owns 1,695 shares of the company’s stock valued at $265,000 after purchasing an additional 413 shares during the last quarter. Summit Global Investments boosted its stake in shares of Johnson & Johnson by 11.3% during the 3rd quarter. Summit Global Investments now owns 4,858 shares of the company’s stock worth $757,000 after acquiring an additional 494 shares in the last quarter. Finally, Sunflower Bank N.A. boosted its stake in shares of Johnson & Johnson by 2.9% during the 3rd quarter. Sunflower Bank N.A. now owns 10,215 shares of the company’s stock worth $1,591,000 after acquiring an additional 285 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Down 1.2 %

JNJ stock opened at $146.82 on Friday. The company has a market cap of $353.80 billion, a price-to-earnings ratio of 9.15, a PEG ratio of 2.45 and a beta of 0.53. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The firm has a 50-day moving average of $155.47 and a two-hundred day moving average of $155.41.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. The business had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. During the same quarter in the prior year, the company posted $2.68 EPS. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. As a group, analysts forecast that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be paid a $1.24 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date is Monday, May 20th. This represents a $4.96 annualized dividend and a dividend yield of 3.38%. Johnson & Johnson’s dividend payout ratio is 29.68%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on JNJ shares. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 17th. Royal Bank of Canada lowered their target price on shares of Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 17th. Raymond James increased their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Monday, April 15th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $175.86.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.